Zelboraf is a second option for melanoma patients with a mutated form of a protein called BRAF that helps with cell growth, when functioning normally. Zelboraf slowed tumor growth by blocking the mutated form of the protein.
Roche estimates that about half of all melanoma patients have the BRAF mutation. Mutations in the BRAF gene may cause the disease in two ways. First, mutations can be inherited and cause birth defects. Second , mutations can occur later in life and cause cancer, as an oncogene. – Hal Barron MD, Chief Medical Officer and Head of Global Product Development, Roche Comments:.Contact:Alison Chapple, Senior Research Fellow at, DIPEx Research Group, stigma of Primary Healthcare, University of Oxford, UK E-mail:.
Whether you them were smoking and non, patient with lung cancer were particularly stigmatized because the disease so strong associated with with smoking and since some of patient died unpleasant way.